PubMed
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension
Ghatei et al., 2003
Immune SupportCompoundableS
VIP
Vasoactive Intestinal Peptide
Vasoactive intestinal peptide (VIP) is a 28-amino acid neuropeptide naturally expressed throughout the nervous system, gut, and immune tissues. It functions as a potent immunomodulator, bronchodilator, and vasodilator. Clinically researched for inflammatory bowel disease, pulmonary arterial hypertension, sarcoidosis, autoimmune conditions, and CIRS (Chronic Inflammatory Response Syndrome). Available through compounding pharmacies with a prescription.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 11
- Research grade
- S
- Experience
- 12
- Activity
- 58
Overall check-ins
Trackers & reports
Overview
About VIP
Vasoactive intestinal peptide (VIP) is a 28-amino acid neuropeptide naturally expressed throughout the nervous system, gut, and immune tissues. It functions as a potent immunomodulator, bronchodilator, and vasodilator. Clinically researched for inflammatory bowel disease, pulmonary arterial hypertension, sarcoidosis, autoimmune conditions, and CIRS (Chronic Inflammatory Response Syndrome). Available through compounding pharmacies with a prescription.
- Category
- Immune Support
- Regulatory status
- Compoundable
- Also known as
- Vasoactive Intestinal Peptide
- Self-reports
- 25
Community
What 25 users report
25 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 2% · Mixed 2% · Unfavorable overall 96%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
163
Energy
6
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
83
Headache
77
Self-reported dose per injection
Median bucket: 50–100 mcg · Most common: 50–100 mcg
Reports span 50–200 mcg
50–100
116
100–200
47
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 88% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 152 days · Based on 24 repeat reporters
Research
Cited research (9)
Source
PubMed
Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo
Delgado et al., 2005
PubMed
Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions
Delgado et al., 2013
PubMed
Vasoactive intestinal peptide: cardiovascular effects
Henning et al., 2001
PubMed
Vasoactive intestinal peptide and the mammalian circadian system
Vosko et al., 2007
PubMed
New perspectives on vasoactive intestinal polypeptide as a widespread modulator of social behavior
Kingsbury, 2015
ClinicalTrials.gov
Vasoactive Intestinal Peptide studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
The significance of vasoactive intestinal peptide in immunomodulation
Delgado et al., 2004
PubMed
Role of vasoactive intestinal peptide in osteoarthritis
Jiang et al., 2016
Tools
Explore more
Explore
More ways to learn about VIP from observational PeptIQ data.
Related peptides
Help
Frequently asked
What do PeptIQ users report about VIP?
This page summarizes 25 anonymized self-reports from PeptIQ users who track VIP, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for VIP?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for VIP?
9 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is VIP safe to use?
This wiki does not assess safety or recommend use. VIP is listed as Compoundable. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of VIP?
This wiki summarizes observational community reports and linked citations for VIP. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for VIP for study-level context — not medical advice.
What is the legal status of VIP?
VIP is listed in PeptIQ as Compoundable. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of VIP?
Safety data quality for VIP varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on VIP?
This page links 9 indexed sources for VIP. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.